Shiga toxin-associated hemolytic uremic syndrome: Specificities of adult patients and implications for critical care management

B Travert, C Rafat, P Mariani, A Cointe, A Dossier… - Toxins, 2021 - mdpi.com
Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS)
is a form of thrombotic microangiopathy secondary to an infection by an enterohemorrhagic …

Bartonella and Coxiella infections presenting as systemic vasculitis: case series and review of literature

…, O Fain, C Philipponnet, X Puéchal, A Dossier… - …, 2022 - academic.oup.com
Objectives Coxiella and Bartonella spp. display particular tropism for endothelial or endocardial
tissues and an abnormal host response to infections with induced autoimmunity. We …

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

…, O Moranne, R Benainous, A Dossier… - Blood, The Journal …, 2021 - ashpublications.org
The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with
immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective controlled …

Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease

…, R Martos, S Loyau, N Lelay, A Dossier… - Annals of the …, 2019 - ard.bmj.com
Objectives Behçet’s disease (BD) is a chronic systemic vasculitis. Thrombosis is a frequent
and life-threatening complication. The pathogenesis of BD is poorly understood and …

Arterial thrombotic events in adult inpatients with COVID-19

M Fournier, D Faille, A Dossier, A Mageau… - Mayo Clinic …, 2021 - Elsevier
Objective To evaluate the clinical course of and risk factors for arterial thrombotic events in
adult inpatients with coronavirus disease 2019 (COVID-19). Methods All consecutive adult …

Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study

…, CY Chan, M Colucci, G Dorval, C Dossier… - Journal of the …, 2022 - journals.lww.com
Background Long-term outcomes after multiple courses of rituximab among children with
frequently relapsing, steroid-dependent nephrotic syndrome (FRSDNS) are unknown. Methods …

[HTML][HTML] Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children

…, M Coenen, CH Cramer, G Deschênes, C Dossier… - Genetics in …, 2022 - Elsevier
Purpose Primary hyperoxaluria type 1 (PH1) is a rare, progressive, genetic disease with
limited treatment options. We report the efficacy and safety of lumasiran, an RNA interference …

[HTML][HTML] Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on …

…, T Yamamura, A Sinha, A Bagga, J Hogan, C Dossier… - Kidney international, 2020 - Elsevier
Rituximab is an effective treatment for steroid-dependent/ frequently-relapsing nephrotic
syndrome (SDFRNS) in children. However, the optimal rituximab regimen remains unknown. To …

Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants

…, J Harambat, D Morin, C Dossier… - Kidney international, 2021 - Elsevier
Autosomal recessive polycystic kidney disease (ARPKD) is a severe disease of early
childhood that is clinically characterized by fibrocystic changes of the kidneys and the liver. The …

Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs

…, E Daugas, V Descamps, P Dieudé, A Dossier… - International journal of …, 2019 - Elsevier
Background We aimed to compare the efficacy of steroids alone or associated with
immunosuppressive drugs for the prevention of relapse in cardiac sarcoidosis (CS). Methods In this …